Nuvalent, Inc. filings document a clinical-stage oncology company developing small-molecule inhibitors for clinically proven kinase targets. Its Form 8-K reports disclose operating and financial results, pipeline and clinical-trial updates for zidesamtinib and neladalkib, FDA submission events, material-event disclosures, and royalty or revenue-share arrangements for its investigational product candidates.
Proxy materials cover annual meeting governance, executive compensation, equity awards, and shareholder voting matters. Other disclosures describe Nuvalent's Class A common stock, capital-structure matters, research and development spending, cash resources, and regulatory considerations associated with advancing ROS1-, ALK-, and HER2-directed cancer programs.
Nuvalent, Inc. (NUVL) Form 4: Henry E. Pelish, the company’s Chief Scientific Officer, reported transactions dated 08/29/2025 that increased his direct holdings. The filing shows two non-derivative additions of 2,007 and 3,000 shares of Class A common stock at reported prices of $0.87 and $1.08, raising his beneficial ownership from 62,963 to 65,963 shares. Corresponding derivative entries show stock options for 2,007 shares exercisable through 12/15/2030 and 3,000 shares exercisable through 02/16/2031. The filer discloses the underlying option shares are fully vested. The submission is signed via attorney-in-fact Nathan N. McConarty on 09/03/2025.
Nuvalent insider transactions by Chief Development Officer Darlene Noci: The filing shows an option exercise and contemporaneous open-market sales done under a Rule 10b5-1 plan. The reporting person exercised a stock option to acquire 4,000 shares at $27.85 on 08/25/2025. On the same date she sold a total of 4,000 Class A shares in multiple transactions at weighted-average prices of $73.96, $74.93, and $75.63, reducing her direct Class A holdings from 52,034 to 48,034 shares. The Form 4 notes the 10b5-1 trading plan was adopted on November 18, 2024, and the reporting person will provide transaction-level sale prices on request.
Nuvalent, Inc. President and CEO James Richard Porter reported an options exercise and same-day share sales. On August 15, 2025, he exercised stock options for 27,000 shares of Class A Common Stock at an exercise price of $18.93 per share and reported sales totaling 27,000 shares at prices in the mid-$70s. The filing states these transactions were effected under a Rule 10b5-1 trading plan adopted on April 2, 2024. After these transactions, he held 249,062 shares of Class A Common Stock directly and retained 276,400 stock options.
Nuvalent insider activity: option exercises and a planned sale under a 10b5-1 plan. Henry E. Pelish, Nuvalent's Chief Scientific Officer, acquired shares through option exercises and sold shares pursuant to a pre-established trading plan. On 08/07/2025 Pelish exercised options to acquire 731 shares at $18.93, 877 shares at $27.85 and 3,892 shares at $29.33, and sold 5,500 shares at $74.85. After these transactions his reported direct beneficial ownership is 60,956 shares. The filing notes the trades were effected under a Rule 10b5-1 plan adopted November 1, 2024, and includes vesting schedules for the options.
Nuvalent, Inc. (NUVL) – Form 144 filing discloses a planned resale of 4,253 Class A common shares, valued at roughly $349,086, through Goldman Sachs & Co. LLC on or after 24 Jul 2025.
The shares were originally acquired in two public offerings (3,535 on 02 Aug 2021 and 718 on 03 Nov 2022) and equal just ~0.006% of the 66.4 million shares outstanding, implying negligible impact on float or dilution because Rule 144 covers already-issued stock. No sales have occurred in the past three months, and the seller certifies possession of no material non-public information.
The notice contains no operational or earnings data and does not involve new capital for the company; however, investors may view insider disposition—albeit small—as a sentiment indicator to be weighed against broader fundamentals.
Nuvalent, Inc. (NUVL) Form 144 reports a planned insider sale of 156,670 Class A common shares, equal to roughly 0.24 % of the 66.37 million shares outstanding. The proposed transaction, to be executed through Goldman Sachs & Co. LLC, carries an aggregate market value of $12.86 million, implying a reference price near $82 per share. The approximate sale date listed is 24 July 2025 on Nasdaq.
The shares were originally acquired on 30 April 2021 via a purchase of preferred stock that automatically converted to common immediately prior to Nuvalent’s IPO. The filer reports no other share sales in the past three months and certifies that no undisclosed material adverse information is known.
While the notice signals insider intent to monetize a portion of holdings, the size is modest versus float and does not by itself alter Nuvalent’s operating outlook. Investors may monitor subsequent Form 4 filings for execution details and gauge any short-term supply effects.